Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma

Pubmed ID: 29741837

Journal:

Cite As: Intermittent Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Mar. (AHRQ Comparative Effectiveness Reviews)

Studies:

Asthma Clinical Research Network Trial (ACRN) - Best Adjustment Strategy for Asthma in Long Term (BASALT) and Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

Abstract

To assess efficacy of intermittent inhaled corticosteroid (ICS) therapy in different populations (0 to 4 years old with recurrent wheezing, 5 years and older with persistent asthma, with or without long-acting beta agonist [LABA]), and to assess efficacy of added long-acting muscarinic antagonist (LAMA) in patients 12 years and older with uncontrolled, persistent asthma.